Serotonin2A (5-HT2A) and 5-HT2C receptors are highly homologous members of the serotonin2 family of 7-transmembrane-spanning (7-TMS) receptors. Both of these receptor subtypes have been implicated in the aetiology and/or treatment of affective disorders such as anxiety and depression. Regulation of dopaminergic neurotransmission by 5-HT2A and 5-HT2C receptor systems has been well established. In general, agonist activation of 5-HT2A receptors can facilitate stimulated dopamine (DA) release, whereas 5-HT2C agonists inhibit dopaminergic neural activity and DA release under both basal and activated conditions. However, recent experimental evidence suggests that 5-HT2A and 5-HT2C receptors can be constitutively active (agonist-independent activity) in vivo. Alterations in the constitutive activity of 5-HT2A and 5-HT2C receptor systems could be involved in the mechanisms underlying anxiety and depression or exploited for therapeutic benefit. Consequently, drugs with inverse agonist properties may have more activity in vivo to regulate DA neurotransmission than that afforded by simple competitive antagonism.